简介: 【摘要】目的 探讨并分析安神补脑液治疗神经衰弱患者的临床疗效。方法 选取 2018年 12月~ 2019年 10月我院收治的患者 147例作为研究对象,将其随机分为试验组 74例和对照组 73例。对照组采用谷维素治疗,试验组采用安神补脑液治疗。比较两组的疗效和生活质量评分。结果 试验组的总有效率为 95.96%较对照组的 78.08%高,生活质量评分较对照组高,差异有统计学意义( P<0.05)。结论 安神补脑液治疗神经衰弱患者的疗效显著,值得推广。 【关键词】神经衰弱;安神补脑液;疗效 [Abstract] Objective To explore and analyze the clinical effect of Anshen Bunao liquid on neurasthenia. Methods 147 patients in our hospital from December 2018 to October 2019 were selected as the research objects, and they were randomly divided into experimental group (74 cases) and control group (73 cases). The control group was treated with oryzanol, and the experimental group was treated with Anshen Bunao liquid. The efficacy and quality of life scores were compared between the two groups. Results the total effective rate of the experimental group was 95.96%, which was higher than 78.08% of the control group, and the score of quality of life was higher than that of the control group (P < 0.05). Conclusion Anshen Bunao liquid has significant effect on neurasthenia patients, which is worthy of promotion.
简介:摘要:目的:探究并分析预见性护理在超窗重症急性心肌梗死患者护理中的效果及SAS、SDS评分影响。方法:通过选取100例来自我院近两年间诊治的超窗重症急性心肌梗死患者,随机平分为两组患者并使用不同护理方法,对照组实施常规护理方法,n=50,观察组在常规护理的基础上使用预见性护理,n=50,对两组不同护理方法下患者的临床效果进行比对。结果:观察组的超窗重症急性心肌梗死患者对比对照组有着更高的护理有效率(P<0.05),观察组患者SAS和SDS分级显著优于对照组(P<0.05),相较于对照组超窗重症急性心肌梗死患者,观察组的患者有着更高的护理满意度(P<0.05)。结论:预见性护理对超窗重症急性心肌梗死患者的护理效果有着显著的提升,同时能够有效提升患者SAS和SDS评分状况,对患者生存质量有着积极的影响,值得临床应用采纳推广。